-

Thermo Fisher Scientific Introduces Fully Integrated Multimodal Analytical Scanning Transmission Electron Microscope to Advance Novel Research in Materials Science

Thermo Scientific Iliad integrates electron energy loss spectroscopy (EELS) and NanoPulser electrostatic beam blanker to improve insights at the atomic level

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, introduced a groundbreaking transmission electron microscope to a packed room of attendees at the recent European Microscopy Congress 2024 in Copenhagen, Denmark. As a fully integrated multimodal analytical solution, the Thermo Scientific™ Iliad™ (Scanning) Transmission Electron Microscope, (S)TEM, gives scientific pioneers deeper insights about the chemical nature of the most sophisticated modern materials, down to the atomic level.

Iliad (S)TEM leverages Thermo Fisher's long history of innovation in scanning transmission electron microscopy, integrating multiple technological modalities into a seamless and user-friendly workflow.

“A revolutionary new platform like this only comes around once in a decade,” said David Wall, vice president and general manager of Materials Science at Thermo Fisher Scientific. “Beginning with its unveiling at EMC, Iliad has already received a positive and energetic reception from researchers and industry leaders across the globe. This is the culmination of years of investment and hard work, but in many ways it’s just the beginning of unlocking the full potential of integrated microscopy technology.”

Leading-edge integration of Iliad hardware and software

Iliad (S)TEM is featuring the new Thermo Fisher Scientific EELS Spectrometer and Energy Filter, as well as the NanoPulser — the new electrostatic beam blanker for the electron dose optimization. Multimodality and the integration of energy dispersive spectroscopy (EDS), EELS and the NanoPulser ensures the advanced and effective approach for precise chemical and structural investigations of broad classes of modern materials.

Iliad is fully controlled with the Thermo Scientific Velox software ecosystem for both spectroscopy and imaging, making the most challenging experiments now accessible to every user. Nearly every component in the Iliad platform can be accessed via Python scripting using Autoscript, opening the possibility of advanced control of the microscope, as well as the adoption of AI-based data collection and processing strategies. The solid interlink of the core modalities of modern (S)TEM enables smooth and reliable workflows for scientists.

Infused with customer insight

Professor Jo Verbeeck, co-leader of Electron Microscopy for Materials Science (EMAT) at the University of Antwerp in Belgium, collaborated on the development of Iliad with the special focus on data quantification. “It’s one thing to write papers on electron energy loss spectroscopy (EELS) quantification, it is far more exciting to see these ideas also implemented in a product that will really change the user experience and reproducibility of EELS,” says Professor Verbeeck, a renowned leader in EELS.

With Iliad, Thermo Fisher Scientific is opening a new chapter of advanced analytical (S)TEM. This completely integrated technology will enable scientists across broad academic and technology sectors to solve scientific problems that make the world healthier, cleaner and safer.

To learn more about Iliad, please visit our website.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Alex Runner
Thermo Fisher Scientific
alex.runner@thermofisher.com

Media Contact Information:
Jessika Parry, Greenough
419-266-4016
jparry@greenoughagency.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Alex Runner
Thermo Fisher Scientific
alex.runner@thermofisher.com

Media Contact Information:
Jessika Parry, Greenough
419-266-4016
jparry@greenoughagency.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom